Prof. Dr. rer. nat. Hans-Georg Rammensee

Publications 2010 - 2011

 

---

2011

Wagner BJ, Löb S, Lindau D, Hörzer H, Gückel B, Klein G, Glatzle J, Rammensee HG, Brücher BL, Königsrainer A. Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin. Int J Oncol. 39(6):1593-600, 2011. PubMed

Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A, Gouttefangeas C, Rammensee HG. Promiscuous survivin peptide induces robust CD4(+) T-cell responses in the majority of vaccinated cancer patients. Int J Cancer. 2011 Aug 19. doi: 10.1002/ijc.26365. [Epub ahead of print]. PubMed

André MC, Sigurdardottir D, Kuttruff S, Pömmerl B, Handgretinger R, Rammensee HG, Steinle A. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction. Int J Cancer. 2011 May 23. doi: 10.1002/ijc.26191. [Epub ahead of print]. PubMed

Wagner BJ, Lindau D, Ripper D, Stierhof YD, Glatzle J, Witte M, Beck H, Keppeler H, Lauber K, Rammensee HG, Königsrainer A. Phagocytosis of dying tumor cells by human peritoneal mesothelial cells. J Cell Sci. 124(Pt 10):1644-54; 2011. PubMed

Haen SP, Gouttefangeas C, Schmidt D, Boss A, Clasen S, von Herbay A, Kosan B, Aebert H, Pereira PL, Rammensee HG. Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation. Cell Stress Chaperones. 2011 Mar 26. [Epub ahead of print]. PubMed

Lindau D, Rönnefarth V, Erbacher A, Rammensee HG, Decker P. Nucleosome-induced neutrophil activation occurs independently of TLR9 and endosomal acidification: Implications for systemic lupus erythematosus. Eur J Immunol. 41(3):669-81; 2011. PubMed

Stickel JS, Stickel N, Hennenlotter J, Klingel K, Stenzl A, Rammensee HG, Stevanović S. Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation. BMC Urol. 20: 11:1; 2011. PubMed

Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P. Intradermal Vaccinations With RNA Coding for TAA Generate CD8(+) and CD4(+) Immune Responses and Induce Clinical Benefit in Vaccinated Patients. Mol Ther. 19(5):990-9; 2011. PubMed

Widenmeyer M, Shebzukhov Y, Haen SP, Schmidt D, Clasen S, Boss A, Kuprash DV, Nedospasov SA, Stenzl A, Aebert H, Wernet D, Stevanović S, Pereira PL, Rammensee HG, Gouttefangeas C. Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. Int J Cancer. 128(11):2653-62; 2011. PubMed

2010

Autenrieth SE, Linzer TR, Hiller C, Keller B, Warnke P, Köberle M, Bohn E, Biedermann T, Bühring HJ, Hämmerling GJ, Rammensee HG, Autenrieth IB. Immune evasion by Yersinia enterocolitica: differential targeting of dendritic cell subpopulations in vivo. PLoS Pathog. 24;6(11):e1001212; 2010. PubMed

Baessler T, Charton JE, Schmiedel BJ, Grünebach F, Krusch M, Wacker A, Rammensee HG, Salih HR. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK cell reactivity against human acute myeloid leukemia cells. Blood 115:3058-3069; 2010. PubMed

Sáenz-López P, Gouttefangeas C, Hennenlotter J, Concha A, Maleno I, Ruiz-Cabello F, Cózar JM, Tallada M, Stenzl A, Rammensee HG, Garrido F, Cabrera T. Higher HLA class I expression in renal cell carcinoma than in autologous tissue. Tissue Antigens 75:110-118; 2010. PubMed

Serangeli C, Bicanic O, Scheible MH, Wernet D, Lang P, Rammensee HG, Stevanovic S, Handgretinger R, Feuchtinger T. Ex vivo detection of adenovirus-specific CD4⁺ T-cell responses to HLA-DR epitopes of the Hexon protein show a contracted specificity of T_HELPER cells following stem cell transplantation. Virology 397:277-284; 2010. PubMed

Prof. Dr. rer. nat. Hans-Georg Rammensee

Publications 2005 - 2009
_________________________________________________________________________________________________________________________________________

 

2009:

Asemissen, A.M., D. Haase, S. Stevanovic, S. Bauer, A. Busse, E. Thiel, H.-G. Rammensee, U. Keilholz, C. Scheibenbogen. 2009. Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2. J. Immunother. 32:370-375.

Attig, S., J. Hennenlotter, G. Pawelec, G. Klein, S.D. Koch, H. Pircher, S. Feyerabend, D. Wernet, A. Stenzl, H.-G. Rammensee, C. Gouttefangeas. 2009. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res. 69:8412-8419.

Bürk, K., M.-L. Farecki, G. Lamprecht, G. Roth, P. Decker, M. Weller, H.-G. Rammensee, W. Oertel. 2009. Neurological symptoms in patients with biopsy proven celiac disease. Mov. Disord. 24:2358-2362.

Diekmann, J., E. Adamopoulou, O. Beck, G. Rauser, S. Lurati, S. Tenzer, H. Einsele, H.-G. Rammensee, H. Schild, M.S. Topp. 2009. Procesing of two latent membrane protein 1 MHC class I epitoeps requires tripeptidyl peptidase II involvement. J. Immunol. 183:1587-1597.

Feyerabend, S., S. Stevanovic, C. Gouttefangeas, D. Wernet, J. Hennenlotter, J. Bedke, K. Dietz, S. Pascolo, M. Kuczyk, H.-G. Rammensee, A. Stenzl. 2009. Novel multi-peptide vaccination in HLA-A2⁺ hormone sensitive patients with biochemical relapse of prostate cancer. The Prostate 69:917-927.

Fissolo, N., S. Haag, K.L. de Graaf, O. Drews, S. Stevanovic, H.-G. Rammensee, R. Weissert. 2009. Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients. Mol. Cell. Proteomics 8:2090-2101.

Hennige, A.M., T. Sartorius, S.Z. Lutz, O. Tschritter, H. Preissl, S. Hopp, A. Fritsche, H.-G. Rammensee, P. Ruth, H.-U. Häring. 2009. Insulin-mediated cortical activity in the slow frequency rang eis diminished in obese mice and promotes physical inactivity. Diabetologia 52:2416-2424.

Kuttruff, S., S. Koch, A. Kelp, G. Pawelec, H.-G. Rammensee, A. Steinle. 2009. NKp80 defines and stimulates a reactive subset of CD8 T cells. Blood 113:358-369

Löb, S., A. Königsrainer, D. Zieker, B.L. Brücher, H.-G. Rammensee, G. Opelz, P. Terness. 2009. ISO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol. Immunother. 58:153-157.

Löb, S., A. Königsrainer, H.-G. Rammensee, G. Opelz, P. Terness. 2009. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nature Rev. Cancer 9:445-452.

Meyer, V.S., O. Drews, M. Günder, J. Hennenlotter, H.-G. Rammensee, S. Stevanovic. 2009. Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands. J. Proteome Res. 8:3666-3674.

Otz, T., L. Große-Hovest, M. Hofmann, H.-G. Rammensee, G. Jung. 2009. A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28-stimulation and killing of lymphoma cells. Leukemia 23:71-77.

Rammensee, H.-G., H. Singh-Jasuja, N. Emmerich, S. Pascolo. 2009. Cancer vaccines: Some basic considerations. In: Genomic and Personalized Medicine. Vol. 1 (Eds.: Willard, H.F. & G.S.Ginsburg), Elsevier, pp. 573-589.

Stickel, J., A.O. Weinzierl, N. Hillen, O. Drews, M.M. Schuler, J. Hennenlotter, D. Wernet, C.A. Müller, A. Stenzl, H.-G. Rammensee, S. Stevanovic. 2009. HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol. Immunother. 58:1407-1417.

Wahlström, J., J. Dengjel, O. Winqvist, I. Targoff, B. Persson, H. Duyar, H.-G. Rammensee, A. Eklund, R. Weissert, J. Grunewald. 2009. Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. Clin. Immunol. 133:353-363.

Weide, B., S. Pascolo, B. Scheel, E. Derhovanessian, A. Pflugfelder, T.K. Eigentler, G. Pawelec, I. Hoerr, H.-G. Rammensee, C. Garbe. 2009. Direct injection of protamine-protected mRNA: Results of a phase 1/2 vaccination trial in metastatic melanoma patients. J. Immunother. 32:498-507.

2008:

Feldhahn, M., P. Thiel, M.M. Schuler, N. Hillen, S. Stevanovic, H.-G. Rammensee, O. Kohlbacher. 2008. EpiToolKit – a web server for computational immunomics. Nucleic Acids Res. E-pub.

Herrmann, T., L. Große-Hovest, T. Otz, P.H. Krammer, H.-G. Rammensee, G. Jung. 2008. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res. 68:1221-1227.

Hillen, N., G. Mester, C. Lemmel, A.O. Weinzierl, M. Müller, D. Wernet, J. Hennenlotter, A. Stenzl, H.-G. Rammensee, S. Stevanovic. 2008. Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype. Eur. J. Immunol. 38:2993-3003.

Kloss, M., P. Decker, K.M. Baltz, T. Baessler, G. Jung, H.-G. Rammensee, A. Steinle, M. Krusch, H.R. Salih. 2008. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J. Immunol. 181:6711-6719.

Löb, S., A. Konigsrainer, R. Schafer, H.-G. Rammensee, G. Opelz, P. Terness. 2008. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111:2152-2154.

Meyer, V.S., W. Kastenmuller, G. Gasteiger, M. Franz-Wachtel, T. Lamkemeyer, H.-G. Rammensee, S. Stevanovic, D. Sigurdardottir, I. Drexler. 2008. Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling. J. Immunol. 181:6371-6383.

Rudolf, D., T. Silberzahn, S. Walter, D. Maurer, J. Engelhard, D. Wernet, H.-J. Bühring, G. Jung, B.S: Kwon, H.-G. Rammensee, S. Stevanović. 2008. Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen-presenting cells. Cancer Immunol. Immunother. 57:175-183.

Schatz, M., B. Peters, N. Akkad, N. Ullrich, A. Nacarino Martinez, O. Carroll, S. Bulik, H.-G. Rammensee, P. van Endert, H.-G. Holzhütter, S. Tenzer, H. Schild. 2008. Characterizing the N-terminal processing motif of MHC class I ligands. J. Immunol. 180:3210-3217.

Tschiedel, S., C. Gentilini, T. Lange, C. Wölfel, T. Wölfel, V. Lennarz, S. Stevanovic, H.-G. Rammensee, C. Huber, M. Cross, D. Niederwieser. 2008. Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia. Leukemia 22:1542-1550.

Wahlström, J., J. Dengjel, B. Persson, H. Duyar, H.-G. Rammensee, S. Stevanovic, A. Eklund, R. Weissert, J. Grunewald. 2008. Identification of HLA-DR-bound peptides prsented by human bronchoalveolar large cells in sarcoidosis. J. Clin. Invest. 117:3576-3582.

Waldhauer, I., D. Goehlsdorf, G. Gieseke, T. Weinschenk, M. Wittenbrink, A. Ludwig, S. Stevanovic, H.-G. Rammensee, A. Steinle. 2008. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 68:6368-6376.

Weide, B., J.-P. Carralot, A. Reese, B. Scheel, T.K. Eigentler, I. Hoerr, H.-G. Rammensee, C. Garbe, S. Pascolo. 2008. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J. Immunother. 31:180-188.

Weide, B., C. Garbe, H.-G. Rammensee, S. Pascolo. 2008. Plasmid DNA and messenger RNA-based anti-cancer vaccination. Immunol. Lett. 115:33-42.

Weinzierl, A.O., D. Maurer, F: Altenberend, N. Schneiderhan-Marra, K. Klingel, O. Schoor, D. Wernet, T. Joos, H.-G. Rammensee, S. Stevanović. 2008. A cryptic vascular endothelial growth factor T-cell epitope: Identification and characterization by mass spectrometry and T-cell assays. Cancer Res. 68:2447-2454.

Weinzierl, A., D. Rudolf, N. Hillen, S. Tenzer, P. van Endert, H. Schild, H.-G. Rammensee, S. Stevanović. 2008. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur. J. Immunol. 38:1503-1510.

Weinzierl, A., D. Rudolf, D. Maurer, D. Wernet, H.-G. Rammensee, S. Stevanović, K. Klingel. 2008. Identification of HLA-A*01- and HLA-A*02-restricted CD8⁺ T-cell epitopes shared among group B enteroviruses. J. Gen. Virol. 89:2090-2097.

Weinzierl, A., G. Szalay, H. Wolburg, M. Sauter, H.-G. Rammensee, R. Kandolf, S. Stevanovic, K. Klingel. 2008.  Effective chemokine secretion by dendritic cells and expansion of cross-presenting CD4-/CD8+ dendritic cells define a protective phenotype in the mouse model of coxsackievirus myocarditis. J. Virol. 82:8149-8160.

Yokoyama, Y., F. Grünebach, S.M. Schmidt, A. Heine, M. Häntschel, S. Stevanovic, H.-G. Rammensee, P. Brossart. 2008. Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin. Cancer Res. 14:5503-5511.

2007:

Adamopoulou E., J. Diekmann, E. Tolosa, G. Kuntz, H. Einsele, H.-G. Rammensee,  M. S. Topp. 2007. Human CD4⁺ T Cells Displaying Viral Epitopes Elicit a Functional Virus-Specific Memory CD8⁺ T Cell Response. J. Immunol.  178: 5465-5472.

Baltz, K.M., M. Krusch, A. Bringmann, P. Brossart, F. Mayer, M. Kloss, T. Baessler, I. Kumbier, A. Peterfi, S.Kupka, S. Kroeber, D. Menzel, M.P. Radsak, H.-G. Rammensee, H.R. Salih. 2007. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J. 21:2442-2454.

Boss, C. N., F. Grünebach, K. Brauer, M Häntschel, V. Mirakaj, T. Weinschenk, S. Stevanović, H.-G. Rammensee, P. Brossart. 2007. Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin. Cancer Res. 13:3347-3355.

Gouttefangeas, C., A. Stenzl, S. Stevanović, H.-G. Rammensee. 2007. Immunotherapy of renal cell carcinoma. Cancer Immunol. Immunother. 56:117-128.

Probst J., B. Weide, B. Scheel, B. J. Pichler, I. Hoerr, H.-G. Rammensee, S. Pascolo. 2007. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther. 14:1175-1180.

Röck, F., K. P. Hadeler, H.-G. Rammensee, P. Overath. Quantitative analysis of murine urine volatiles: in search of MHC-dependent differences. 2007. PloS ONE 2:e429.

Wahlström J. J. Dengjel, B. Persson, H. Düyar, H.-G. Rammensee, S. Stevanović, A. Eklund, R. Weissert, J. Grunewald. 2007. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J. Clin. Invest. 117:3576-3582.

Weinzierl, A.O., C. Lemmel, O. Schoor, M. Müller, T. Krüger, D. Wernet, J. Hennenlotter, A. Stenzl, K. Klingel, H.-G. Rammensee, S. Stevanović. 2007. Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol. Cell. Proteomics 6:102-113.

2006:

Asemissen, A.-M., U. Keilholz, S. Tenzer, M. Müller, S. Walter, S. Stevanovic, H. Schild, A. Letsch, E. Thiel, H.-G. Rammensee, C. Scheibenbogen. 2006. identification of a highly immunogenic HLA-A*01-binding T-cell epitope of WT1. Clin. Cancer Res. 12:7476-7482.

Decker, P., I. Kötter, R. Klein, B. Berner, H.-G. Rammensee. 2006. Monocyte-dervied dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Rheumatology 45:1087-1095.

Dengjel, J., M.-D. Nastke, C. Gouttefangeas, G. Gitsioudis, O. Schoor, F. Altenberend, M. Müller, B. Krämer, A. Missiou, M. Sauter, J. Hennenlotter, D. Wernet, A. Stenzl, H.-G. Rammensee, K. Klingel, S. Stevanovic. 2006. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin. Cancer Res. 12:4163-4170.

Osterloh, P., K. Linkemann, S. Tenzer, H.-G. Rammensee, M.P. Radsak, D.H. Busch, H. Schild. 2006. Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. Proc. Natl. Acad. Sci. USA 103:5042-5047.

Probst, J., S. Brechtel, B. Scheel, I. Hoerr, G. Jung, H.-G. Rammensee, S. Pascolo. 2006. Characterization of the ribonuclease activity on the skin surface. Genetic Vaccines Ther. 4:4 (on-line).

Rammensee, H.-G. 2006. Peptides made to order. Immunity 25:693-695.

Rammensee, H.-G. 2006. Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer. Immunol. Cell Biol. 84:290-294.

Rechtsteiner, G., T. Warger, M. Hofmann, H.-G. Rammensee, H. Schild, M.P. Radsak. 2006. Precursor frequency can compensate for lower TCR expression in T cell competition during priming in vivo. Eur. J. Immunol. 36:2613-2623.

Röck, F., S. Mueller, U. Weimar, H.-G. Rammensee, P. Overath. 2006. Comparative analysis of volatile constituents from mice and their urine. J. Chem. Ecol. 32:1333-1346.

Rönnefarth, V.M., A.I.M. Erbacher, T. Lamkemeyer, J. Madlung, A. Nordheim, H.-G. Rammensee, P. Decker. 2006. TLR2/TLR4-independent neutrophil activation and recruitment upon endocytosis of nucleosomes reveals a new pathway of innate immunity in systemic lupus erythematosus. J. Immunol. 177:7740-7749.

Scheel, B., S. Aulwurm, J. Probst, L. Stitz, I. Hoerr, H.-G. Rammensee, M. Weller, S. Pascolo. 2006. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur. J. Immunol. 36:2807-2816.

Warger, T., N. Hilf, G. Rechtsteiner, P. Haselmayer, D.M. Carrick, H. Jonuleit, P. von Landenberg, H.-G. Rammensee, C.V. Nicchitta, M.P. Radsak, H. Schild. 2006. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of GP96 amplifies innate and adaptive immune responses. J. Biol. Chem. 281:22545-22553.

2005:

Carralot, J.-P., C. Dumrese, R. Wessel, R. Riessen, I. Autenrieth, S. Walter, O. Schoor, S. Stevanovic, H.-G. Rammensee, S. Pascolo. 2005. CD8⁺ T cells specific for a potential HLA-A*0201 epitope from Chlamydophila pneumoniae are present in the PBMCs from infected patients. Int. Inmunol. 17:591-597.

Carralot, J.-P., B. Weide, O. Schoor, J. Probst, B. Scheel, R. Teufel, I. Hörr, C. Garbe, H-G. Rammensee, S. Pascolo. 2005. Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. Genet. Vaccines Ther. 3:6.

Decker, P., H. Singh-Jasuja, S. Haager, I. Kotter, H.-G. Rammensee. 2005. Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J. Immunol. 174:3326-3334.

Dengjel, J., H.-G. Rammensee, S. Stevanovic. 2005. Glycan side chains on naturally presented MHC class II ligands. J. Mass Spectrom. 40:100-104.

Dengjel, J., O. Schoor, R. Fischer, M. Reich, M. Kraus, M. Müller, K. Kreymborg, F. Altenberend, J. Brandenburg, H. Kalbacher, R. Brock, C. Driessen, H.-G. Rammensee, S. Stevanovic. 2005. Autophagy promotes MHC class II presentation of peptides form intracellular source proteins. Proc. Natl. Acad. Sci. USA 102:7922-7927.

Dittmann, J., K. Keller-Matschke, T. Weinschenk, T. Kratt, T. Heck, H.-D. Becker, S. Stevanovic, H.-G. Rammensee, C. Gouttefangeas. 2005. CD8⁺ T-cell response against MUC-1-derived peptides in gastrointestinal cancer survivors. Cancer Immunol., Immunother. 54:750-758.

Grosse-Hovest, L., W. Wick, R. Minoia, M. Weller, M, H.-G. Rammensee, G. Brem, G. Jung. 2005. Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. Int. J. Cancer 117:1060-1064.

Herter, S., P. Osterloh, N. Hilf, G. Rechtsteiner, J. Höhfeld, H.-G. Rammensee, H. Schild. 2005. Dendritic cell aggresome-like-induced structure formation and delayed antigen presentation coincide in influenza virus-infected dendritic cells. J. Immunol. 175:891-898.

Jung, G., Herrmann, T., Grosse-Hovest, L., Salih, H.R., Rammensee, H.-G.: Monoclonal and bispecific antibodies as novel therapeutics. Chapter XI. In: Los, M., Gibson, S.B. (Eds) Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases. Springer, Berlin, 229 – 242 (2005)

Kramer, B.F., O. Schoor, T. Kruger, C. Reichle, M. Muller, T. Weinschenk, J. Hennenlotter, A. Stenzl, H.-G. Rammensee, S. Stevanovic. 2005. MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol. Ther. 4:943-948.

Krüger, T., O. Schoor, C. Lemmel, B. Krämer, C. Reichle, J. Dengjel, T. Weinschenk, M. Müller, J. Hennenlotter, A. Stenzl, H.-G. Rammensee, S. Stevanovic. 2005. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol., Immunother. 54:826-836.

Nastke, M.-D., L. Herrgen, S. Walter, D. Wernet, H.-G. Rammensee, S. Stevanovic. 2005. Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire. Cell. Mol. Life Sci. 62:77-86.

Neumeister, B., M. Faigle, D. Spitznagel, A. Mainka, A. Ograbek, H. Wieland, N. Mannowetz, H.-G. Rammensee. 2005. Legionella pneumophila down-regulates MHC class I expression of human monocytic host cells and thereby inhibits T cell activation. Cell. Mol. Life Sci. 62:578-588.

Pascolo, S., F. Ginhoux, N. Laham, S. Walter, O. Schoor, J. Probst, P. Rohrlich, F. Obermayr, P. Fisch, O. Danos, R. Ehrlich, F.A. Lemonnier, H.-G. Rammensee. 2005. The non-classical HLA class I molecule HFE does not influence the NK-like activity contained in fresh human PBMCs and does not interact with NK cells. Int. Immunol.17:117-122.

Ramirez, S.R., H. Singh-Jasuja, T. Warger, S. Braedel-Ruoff, N. Hilf, K. Wiemann, H.G. Rammensee, H. Schild. Glycoprotein 96-actiated dendritic cells induce a CD8-biased T-cell response. 2005. Cell Stress Chaperones 10:221-229.

Scheel, B., R. Teufel, J. Probst, J.-P. Carralot, J. Geginat, M. Radsak, D. Jarrossay, H. Wagner, G. Jung, H.-G. Rammensee, I. Hörr, S. Pascolo. 2005. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur. J. Immunol. 35:1557-1566.

Schilbach, K., G. Kerst, S. Walter, M. Eyrich, D. Wernet, R. Handgretinger, W. Xie, H.-G. Rammensee, I. Müller, H.-J. Bühring, D. Niethammer. 2005. Cytotoxic minor histocompatibility antigen HA-1-specific CD8⁺ effector memory T cells: Artificial APCs pave the way for clinical application by potent primary in vitro induction. Blood 106:144-149.

Schuler, M.M., P. Donnes, M.-D. Nastke, O. Kohlbacher, H.-G. Rammensee, S. Stevanovic. 2005. SNEP: SNP-derived epitope prediction program for minor H antigens. Immunogenetics 57:816-820.

Tammiruusu, A., A. Haveri, S. Pascolo, R. Lahesmaa, S. Stevanovic, H.-G. Rammensee, M. Sarvas, M. Puolakkainen, J.M. Vuola. 2005. Clearance of Chlamydia pneumoniae infection in H-2 class I^-/- human leucocyte antigen-A2.1 monochain transgenic mice. Scand. J. Immunol. 62:131-139.

Tenzer, S., B. Peters, S. Bulik, O. Schoor, C. Lemmel, M.M. Schatz, P.M. Kloetzel, H.-G. Rammensee, H. Schild, H.G. Holzhütter. 2005. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol. Life Sci. 62:1025-1037.

Teufel, R., J.-P. Carralot, B. Scheel, J. Probst, S. Walter, G. Jung, I. Hörr, H.-G. Rammensee, S. Pascolo. 2005. Human peripheral blood mononuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T lymphocytes in vitro. Cell Mol. Life Sci. 62:1755-1762.

Walter, S., G. Bioley, H.J. Bühring, S. Koch, D. Wernet, A. Zippelius, G. Pawelec, P. Romero, S. Stevanovic, H.-G. Rammensee, C. Gouttefangeas. 2005. High frequencies of functionally impaired cytokeratin 18-specific CD8⁺ T cells in healthy HLA-A2⁺ donors. Eur. J. Immunol. 35:2876-2885.

Wiemann, K., H.W. Mittrücker, U. Feger, S.A. Welte, W.M. Yokoyama, T. Spies, H.-G. Rammensee, A. Steinle. 2005. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J. Immunol. 175:720-729.

Prof. Dr. rer. nat. Hans-Georg Rammensee

Important publications (selection)
____________________________________________________________________________________________________________________________________________

Lob, S., A. Konigsrainer, H. G. Rammensee, G. Opelz, and P. Terness. 2009. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 9:445. Pubmed

Feyerabend, S., S. Stevanovic, C. Gouttefangeas, D. Wernet, J. Hennenlotter, J. Bedke, K. Dietz, S. Pascolo, M. Kuczyk, H. G. Rammensee, and A. Stenzl. 2009. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 69:917. Pubmed

Weide, B., J. P. Carralot, A. Reese, B. Scheel, T. K. Eigentler, I. Hoerr, H. G. Rammensee, C. Garbe, and S. Pascolo. 2008. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother. 31:180. Pubmed

Osterloh, P., K. Linkemann, S. Tenzer, H. G. Rammensee, M. P. Radsak, D. H. Busch, and H. Schild. 2006. Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. Proc. Natl. Acad. Sci. U. S. A 103:5042.Pubmed

Rammensee, H.-G. 2006. Peptides made to order. Immunity 25:693-695. Pubmed

Dengjel, J., O. Schoor, R. Fischer, M. Reich, M. Kraus, M. Muller, K. Kreymborg, F. Altenberend, J. Brandenburg, H. Kalbacher, R. Brock, C. Driessen, H. G. Rammensee, and S. Stevanovic. 2005. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc. Natl. Acad. Sci. U. S. A 102:7922. Pubmed

Rammensee, H.-G. 2004. New and Views: Immunology: Protein surgery. Nature 427:203-204. Pubmed

Lemmel, C., S. Weik, U. Eberle, J. Dengjel, T. Kratt, H. D. Becker, H. G. Rammensee, and S. Stevanovic. 2004. Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat. Biotechnol. 22:450. Pubmed

Dengjel, J., P. Decker, O. Schoor, F. Altenberend, T. Weinschenk, H. G. Rammensee, and S. Stevanovic. 2004. Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry. Eur. J Immunol. 34:3644. Pubmed

Drexler, I., C. Staib, W. Kastenmuller, S. Stevanovic, B. Schmidt, F. A. Lemonnier, H. G. Rammensee, D. H. Busch, H. Bernhard, V. Erfle, and G. Sutter. 2003. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc. Natl. Acad. Sci. U. S. A 100:217. Pubmed

Rammensee, H.-G. 2002. Survival of the fitters. Nature 419:443-445. Pubmed

Weinschenk, T., C. Gouttefangeas, M. Schirle, F. Obermayr, S. Walter, O. Schoor, R. Kurek, W. Loeser, K. H. Bichler, D. Wernet, S. Stevanovic, and H. G. Rammensee. 2002. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62:5818. Pubmed

Rammensee, H. G., T. Weinschenk, C. Gouttefangeas, and S. Stevanovic. 2002. Towards patient-specific tumor antigen selection for vaccination. Immunol. Rev. 188:164. Pubmed

Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs. First listing. Immunogenetics 41:178-228. Pubmed

Falk, K., O. Rötzschke, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290-296. Pubmed
Comment in  J Immunol. 2006;177(5):2741-7. Pubmed

Rötzschke, O., K. Falk, K. Deres, H. Schild, M. Norda, J. Metzger, G. Jung, and H.-G. Rammensee. 1990. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348:252-254. Pubmed

Falk, K., O. Rötzschke, and H.-G. Rammensee. 1990. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 348:248-251. Pubmed

Rötzschke, O., K. Falk, H.-J. Wallny, S. Faath, and H.-G. Rammensee. 1990. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science 249:283-287. Pubmed

Wallny, H.-J. and H.-G. Rammensee. 1990. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 343:275-278. Pubmed

Rammensee, H.-G. R. Kroschewski, and B. Frangoulis. 1989. Clonal anergy induced in mature Vß6+ T lymphocytes on immunizing Mls-1b mice with Mls-1a expressing cells. Nature 339:541-544. Pubmed

Deres, K., H. Schild, K.-H. Wiesmüller, G. Jung, and H.-G. Rammensee. 1989. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342:561-564. Pubmed

Rammensee, H. G., P. J. Robinson, A. Crisanti, and M. J. Bevan. 1986. Restricted recognition of beta 2-microglobulin by cytotoxic T lymphocytes. Nature 319:502-504. Pubmed

Rammensee, H. G. and M. J. Bevan. 1984. Evidence from in vitro studies that tolerance to self antigens is MHC-restricted. Nature 308:741-744. Pubmed

 

 

Prof. Dr. rer. nat. Hans-Georg Rammensee

Scientific Profile
_______________________________________________________________________________________________________________________________________________________________________________________________________

I started to work on immunology in 1979, with the specific aim of using tumor immunology to fight against cancer. My first research projects were on minor histocompatibility antigens, which revealed some similarity to tumor antigens: weak immunogens, MHC-restricted, nature completely unknown at that time. After contributing to the areas of genetics and immune regulation (“veto cells”), I showed that central tolerance to such antigens is MHC restricted (Rammensee HG, Bevan MJ., Nature 1984; 308:741). Later, I identified the first minor H antigen (Rammensee HG et al., Nature 1986; 319:502).
After setting up my own research group, we 1) showed that minor H antigens are peptides presented by MHC (Nature 1990; 343:275, Science 1990; 249:283); 2) identified the first naturally processed viral T cell epitopes (Nature 1990; 348:252; 634 citations), 3) for the first time eluted and identified peptides directly from MHC, and discovered the nature of MHC peptide specificity (“motifs”) (Nature 1991; 351:290; 1882 citations; featured in “pillars of immunology”, J Immunol. 2006 Sep 1; 177(5):2741-7), 4) showed that MHC itself contributes to processing of peptides (Nature 1990; 348:248), 5) demonstrated, for the first time, induction of T cell anergy in vivo (Nature 1989; 339: 541; 542 citations), 6) used a covalent peptide/TLR-ligand compound for efficient immunization (Nature 1989; 342:561; 521 citations). Building on the MHC/peptide work, we were the first group to exactly predict T cell epitopes. We then systematically developed bioinformatic tools for this purpose, e.g., our database SYFPEITHI, which is the gold standard in this field (Immunogenetics 1995; 41:178; 1212 citations).
Several of my former PhD students or postdocs have achieved leading positions. E.g., my first PhD student, Hansjörg Schild, is now chair of Immunology at the University of Mainz; Christian Münz is full professor for Experimental Immunology at the University of Zürich, Dept. of Pathology, and thus, the successor of Rolf Zinkernagel; Alexander Steinle is full professor for Molecular Medicine at the University of Frankfurt/M; Olaf Rötzschke is group leader at the Singapore Immunology Network (BIOPOLIS); Eckhard Lammert is full professor and chair of the Institute for Zoophysiology at the University of Düsseldorf; and Harpreet Singh is CSO of immatics biotechnologies.
More recently, I am frequently invited to write comments on new developments in immunology by the leading journals, e.g., Rammensee HG. Peptides made to order. Immunity. 2006; 25:693; Rammensee HG. Immunology: protein surgery. Nature. 2004; 427:203; Rammensee HG. Survival of the fitters. Nature. 2002; 419:443.
In recent years, we have combined basic research on MHC biology with translational research; thus, I could build upon 20 years of research by finally bringing tumor immunology into clinical practice, together with expert clinicians. This work has led already to two flourishing spin-off companies (immatics and CureVac), both in clinical phase I and phase II trials. Please look in the ASCO 2010 (June 4th – 8th in Chicago) reports on their latest results! I now intend to use the next 10 years to bring truly individualized cancer immunotherapy (something big pharma is not interested so far) into the clinic, taking advantage of the latest technological advances in genome sequencing and peptidome analysis.

Prof. Dr. rer. nat. Hans-Georg Rammensee

Scientific Career History

2008 – present	Director, Interfaculty Institute for Cell Biology, University of Tübingen, Germany
2010	Co-founder of the biotechnology enterprise SYNIMMUNE GmbH
2000	Co-founder of the biotechnology enterprises immatics GmbH and CureVac GmbH
1996 – present	Chair, Department of Immunology (Full Professor, C4), Interfaculty Institute for Cell Biology, University of Tübingen, Germany
1993 – 1996	Head of Department, Tumor-Virus-Immunology Section, German Cancer Research Center (DKFZ), Heidelberg; appointment as Professor, University of Heidelberg
1991	Habilitation in immunology at the University of Tübingen
1988 – 1993	Academic teaching duties at the Universities of Tübingen and Heidelberg
1987 – 1993	Group leader at the Department of Immunogenetics, Max Planck Institute for Biology, Tübingen, Germany
1985 – 1987	Scientific Member of the Basel Institute for Immunology (Minor H antigens and self tolerance)
1982 – 1985	Postdoctoral research fellow in the laboratory of Michael J. Bevan, Ph.D., at Scripps Clinic, La Jolla, CA, USA (Self tolerance of cytotoxic T lymphocytes)
1980 – 1982	PhD thesis in the laboratory of Professor Dr. Jan Klein at the Max-Planck-Institute for Biology, Tübingen, Germany. (Minor histocompatibility antigens)
1980	Diploma thesis in the laboratory of Professor Dr. Jan Klein at the Max-Planck-Institute for Biology, Tübingen, Germany
1974 – 1980	Study of biology at the University of Tübingen, Germany